EX9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High Profitability & MarginsSustained, very high margins indicate structural pricing power and low COGS for its small‑molecule portfolio. Durable profitability supports reinvestment in R&D, continued capital returns and resilience through revenue cycles, improving long‑term free cash flow conversion.
Strong Cash Generation & Low LeverageConsistent high operating and free cash flow plus a large cash balance and minimal leverage give durable financial flexibility. This enables funding of pivotal trials, buybacks, and partnerships without reliance on dilutive or costly external financing over the medium term.
Commercial Momentum & Pipeline ProgressDouble‑digit prescription growth and rising market share demonstrate sustainable commercial execution of the cabo franchise. Concurrent ZANZA regulatory progress and multiple pivotal STELLAR trials diversify future revenue streams and indicate a credible path to franchise expansion beyond cabo.
Bears Say
Rising Gross‑to‑Net DeductionsStructural increases in 340B volumes, Medicare Part D discounts and co‑pay assistance compress net realized revenue per unit. Persistently higher gross‑to‑net reduces durable top‑line conversion and can erode long‑run margins absent offsetting price or mix improvements.
Revenue Concentration & LumpinessHeavy reliance on a single franchise and milestone/timing‑sensitive collaboration income increases structural volatility in revenues and cash flow. This concentration makes long‑term growth dependent on sustaining cabo sales and limits diversification until new assets reach commercial scale.
Pipeline & Regulatory Timing RiskFuture growth materially depends on several timing‑sensitive pivotal trials and regulatory outcomes. Delays, immature endpoints, or negative readouts would materially affect long‑term revenue trajectories, making the company’s durable prospects contingent on successful late‑stage execution.
Exelixis News
EX9 FAQ
What was Exelixis’s price range in the past 12 months?
Currently, no data Available
What is Exelixis’s market cap?
Currently, no data Available
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Aug 05, 2026 which is in 11 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on May 05, 2026. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.622 by $0.088.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.7.
How many shares outstanding does Exelixis have?
Currently, no data Available
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.71 in its last earnings report, beating expectations of $0.622. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in CH:EX9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$42.17 (― Downside)
$42.17 (― Downside)
Insider Transactions
Sold Shares
Worth CHF9.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.59%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
EX9 Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
EX9 Stock 12 Month Forecast
Average Price Target
$42.17